Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Nestlé_Health_Science
|
| gptkbp:acquisitionYear |
2020
|
| gptkbp:CEO_(as_of_2020) |
gptkb:Andrew_Oxtoby
|
| gptkbp:focusesOn |
food allergy treatments
|
| gptkbp:founded |
2011
|
| gptkbp:founder |
gptkb:Stephen_Dilly
|
| gptkbp:headquarters_location |
gptkb:Brisbane,_California,_United_States
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:notableProduct |
gptkb:Palforzia
|
| gptkbp:number_of_employees_(2020) |
approximately 300
|
| gptkbp:Palforzia_indication |
peanut allergy
|
| gptkbp:parentOrganization |
gptkb:Nestlé_Health_Science
|
| gptkbp:researchInterest |
oral immunotherapy
|
| gptkbp:servesArea |
gptkb:Europe
gptkb:United_States |
| gptkbp:stockSymbol |
gptkb:AIMT
|
| gptkbp:type |
gptkb:subsidiary
|
| gptkbp:website |
https://www.aimmune.com/
|
| gptkbp:bfsParent |
gptkb:Sofinnova_Investments
|
| gptkbp:bfsLayer |
6
|
| https://www.w3.org/2000/01/rdf-schema#label |
Aimmune Therapeutics
|